###begin article-title 0
A Ribosomal S-6 Kinase-Mediated Signal to C/EBP-beta Is Critical for the Development of Liver Fibrosis
###end article-title 0
###begin p 1
Conceived and designed the experiments: MC MB. Performed the experiments: MB. Analyzed the data: MC MB. Wrote the paper: MC MB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
In response to liver injury, hepatic stellate cell (HSC) activation causes excessive liver fibrosis. Here we show that activation of RSK and phosphorylation of C/EBPbeta on Thr217 in activated HSC is critical for the progression of liver fibrosis.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 86 89 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 422 425 407 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 439 440 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 495 496 480 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 767 772 <span type="species:ncbi:9606">human</span>
###xml 794 799 <span type="species:ncbi:9606">human</span>
###xml 837 845 <span type="species:ncbi:9606">patients</span>
###xml 952 957 <span type="species:ncbi:9606">human</span>
Chronic treatment with the hepatotoxin CCl4 induced severe liver fibrosis in C/EBPbeta+/+ mice but not in mice expressing C/EBPbeta-Ala217, a non-phosphorylatable RSK-inhibitory transgene. C/EBPbeta-Ala217 was present within the death receptor complex II, with active caspase 8, and induced apoptosis of activated HSC. The C/EBPbeta-Ala217 peptides directly stimulated caspase 8 activation in a cell-free system. C/EBPbeta+/+ mice with CCl4-induced severe liver fibrosis, while continuing on CCl4, were treated with a cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK activation, stimulating apoptosis of HSC, preventing progression and inducing regression of liver fibrosis. We found a similar activation of RSK and phosphorylation of human C/EBPbeta on Thr266 (human phosphoacceptor) in activated HSC in patients with severe liver fibrosis but not in normal livers, suggesting that this pathway may also be relevant in human liver fibrosis.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
These data indicate that the RSK-C/EBPbeta phosphorylation pathway is critical for the development of liver fibrosis and suggest a potential therapeutic target.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 77 80 77 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-1">[1]</xref>
###xml 118 121 118 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-2">[2]</xref>
###xml 235 238 235 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chung1">[3]</xref>
###xml 314 317 314 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier1">[4]</xref>
###xml 554 557 554 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 557 560 557 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Lee1">[6]</xref>
###xml 636 639 636 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Friedman1">[7]</xref>
###xml 640 643 640 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-AnkomaSey1">[9]</xref>
The annual worldwide mortality from liver cirrhosis is approximately 800,000 [1], and there is no available treatment [2]. Excessive tissue repair in chronic liver diseases induced by viral, toxic, immunologic, and metabolic disorders [3], results in the deposition of scar tissue and the development of cirrhosis [4]. Quiescent hepatic stellate cells (HSC) produce negligible amounts of extracellular matrix proteins (ECM), but after their activation, these cells develop a myofibroblastic phenotype, proliferate and become the main contributors of ECM [5][6]. This step is required for the development of liver fibrosis and cirrhosis [7]-[9].
###end p 9
###begin p 10
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-SassoneCorsi1">[14]</xref>
###xml 250 253 244 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 253 257 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 393 397 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Nakajima1">[15]</xref>
###xml 491 495 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 603 606 594 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 652 656 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 174 179 <span type="species:ncbi:10090">mouse</span>
###xml 233 238 <span type="species:ncbi:9606">human</span>
###xml 555 560 <span type="species:ncbi:10090">mouse</span>
###xml 565 570 <span type="species:ncbi:9606">human</span>
The mitogen-activated protein kinase (MAPK) pathway, through the extracellular signal-regulated kinase (ERK1/2), activates RSK [10]-[14], resulting in the phosphorylation of mouse C/EBPbeta (NP_034013 XP_916631) on Thr217 (Thr266 in human C/EBPbeta) [5][10]. The RSK pathway may be critical for HSC activation induced by liver injury, because expression of a catalytically inactive mutant RSK [15], blocked proliferation and survival of cultured HSC upon their activation by collagen type 1 [10]. The RSK phosphoacceptor site in C/EBPbeta is identical in mouse and human, it is evolutionarily conserved [5], and essential for survival of activated HSC [10].
###end p 10
###begin p 11
###xml 186 187 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 301 305 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 305 309 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Rudolph1">[16]</xref>
###xml 442 443 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 486 489 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 728 731 710 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 788 790 770 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 824 825 806 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1076 1077 1058 1059 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 218 224 <span type="species:ncbi:9606">humans</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
###xml 732 736 <span type="species:ncbi:10090">mice</span>
###xml 1055 1059 <span type="species:ncbi:10090">mice</span>
###xml 1137 1142 <span type="species:ncbi:9606">human</span>
###xml 1186 1191 <span type="species:ncbi:9606">human</span>
###xml 1242 1250 <span type="species:ncbi:9606">patients</span>
Here we show that activation of RSK and phosphorylation of C/EBPbeta on Thr217 in activated HSC is critical for the progression of liver fibrosis. Chronic exposure to the hepatotoxin CCl4 can induce liver cirrhosis in humans, and it is a classical method of inducing liver injury and fibrosis in mice [10][16]. We used this model to investigate the role of RSK and phosphorylation of C/EBPbeta on Thr217 in liver fibrosis. The hepatotoxin CCl4 induced severe liver fibrosis in C/EBPbeta+/+ mice but not in mice expressing C/EBPbeta-Ala217, a non-phosphorylatable RSK-inhibitory transgene. C/EBPbeta-Ala217 was present within the death receptor complex II, with active caspase 8, and induced apoptosis of activated HSC. C/EBPbeta+/+ mice with severe liver fibrosis induced by an 8-week CCl4 treatment, while continuing on CCl4, were treated with a cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK activation, stimulating apoptosis of HSC, preventing progression and inducing regression of liver fibrosis compared to control mice treated with CCl4. We found similar activation of RSK and phosphorylation of human C/EBPbeta (NP_005185) on Thr266 (identical human phosphoacceptor) in activated HSC in the liver of patients with severe liver fibrosis. These data indicate that the RSK-C/EBPbeta phosphorylation pathway is critical for the development of liver fibrosis, and that inhibition of the RSK pathway is a potential therapeutic strategy for the prevention and treatment of liver cirrhosis.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice expressing the RSK-inhibitory C/EBPbeta-Ala217 transgene are resistant to hepatotoxin-induced liver fibrosis
###end title 13
###begin p 14
###xml 57 61 57 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 304 305 301 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 419 423 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 423 427 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Rudolph1">[16]</xref>
###xml 791 795 782 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 336 342 <span type="species:ncbi:9606">humans</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
Given the important role of RSK in the activation of HSC [10], we hypothesized that a RSK-inhibitory transgenic protein would block phosphorylation of C/EBPbeta on Thr217, induce HSC apoptosis and decrease liver fibrosis following chronic liver injury. Because the chronic exposure to the hepatotoxin CCl4 can induce liver cirrhosis in humans, and it is a classical method of inducing liver injury and fibrosis in mice [10][16], we analyzed whether it induces liver cirrhosis in mice expressing the dominant negative, nonphosphorylatable RSK-inhibitory C/EBPbeta-Ala217 transgene. This mutation changes the phosphorylatable Thr217 to a nonphosphorylatable Ala217 within the RSK phosphoacceptor site of C/EBPbeta. These animals are developmentally normal, fertile and have a normal life span [10], suggesting that the RSK-inhibitory transgene is apparently not toxic.
###end p 14
###begin p 15
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Constandinou1">[17]</xref>
###xml 752 755 741 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier1">[4]</xref>
###xml 755 758 744 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Friedman1">[7]</xref>
###xml 758 761 747 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bataller1">[8]</xref>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
###xml 240 246 <span type="species:ncbi:9606">humans</span>
After the thrice-weekly intraperitoneal administration of CCl4 for 12 weeks, we determined the degree of liver fibrosis in coded samples. This is an extensive chronic exposure for mice and comparable to established severe liver fibrosis in humans [17]. We evaluated liver fibrosis employing the following methods: i) microscopic morphology; ii) semi-quantitative METAVIR clinical grading system; iii) collagen type 1 immunofluorescence; iv) quantitative Sirius red collagen-binding assay; v) quantitative hydroxyproline collagen content; vi) RT-PCR for collagen type 1 mRNA; vii) RT-PCR for alpha-smooth muscle actin (alpha-SMA) mRNA (present in activated HSC); and viii) RT-PCR for transforming growth factor (TGF-beta) mRNA (a pro-fibrotic cytokine) [4][7][8].
###end p 15
###begin p 16
###xml 169 172 166 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 199 200 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 270 279 267 276 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</underline>
###xml 270 279 267 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1A</underline></xref>
###xml 281 284 278 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier1">[4]</xref>
###xml 284 287 281 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bataller1">[8]</xref>
###xml 372 376 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bedossa1">[18]</xref>
###xml 402 404 399 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 428 431 422 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 473 474 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 556 557 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 571 572 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 578 579 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 589 598 580 589 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</underline>
###xml 589 598 580 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1A</underline></xref>
###xml 752 754 743 745 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 790 799 778 787 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</underline>
###xml 790 799 778 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1B</underline></xref>
###xml 977 980 959 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 996 998 978 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 1009 1018 991 1000 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S1</underline>
###xml 1009 1018 991 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001372.s002"><underline>Figure S1</underline></xref>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 784 788 <span type="species:ncbi:10090">mice</span>
###xml 950 954 <span type="species:ncbi:10090">mice</span>
###xml 981 985 <span type="species:ncbi:10090">mice</span>
Liver samples were stained with the classical Mallory's trichrome to identify collagen in the extracellular matrix. The hepatic collagen pattern and content of C/EBPbeta+/+ (wt) mice treated with CCl4 for 12 weeks were similar to those of patients with liver cirrhosis (Figure 1A) [4][8]. We graded the coded liver samples with the standard 0 to 4 METAVIR clinical system [18], and found that after CCl4 treatment, all C/EBPbeta+/+ mice had severe liver fibrosis (grade 4; n: 12), while all C/EBPbeta-Ala217 mice had minimal or no liver fibrosis (grade 0; n: 6; grade 1; n: 6) (P<0.0001) (Figure 1A). In agreement with the findings with the Mallory's trichrome, the Sirius red collagen-binding stain also demonstrated decreased liver fibrosis after CCl4 treatment in C/EBPbeta-Ala217 mice (Figure 1B). Similarly, confocal scanning microscopy with specific antibodies against collagen type 1 also identify decreased liver fibrosis in C/EBPbeta-Ala217 mice, compared to C/EBPbeta+/+ mice, after CCl4 treatment (Figure S1). Although the intra- and inter-observer variability in the semi-quantitative analysis of liver fibrosis was low, we confirmed these findings using quantitative analysis of liver fibrosis.
###end p 16
###begin title 17
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice expressing the RSK-inhibitory C/EBPbeta-Ala217 transgene are refractory to the induction of liver fibrosis.
###end title 17
###begin p 18
###xml 9 12 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 49 53 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722; </sup>
###xml 99 100 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 155 162 146 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 263 266 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 278 279 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 340 341 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 347 355 332 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.0001</italic>
###xml 370 374 352 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722; </sup>
###xml 380 381 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 386 392 368 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 620 623 599 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 666 669 639 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 816 819 774 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 841 842 799 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 844 845 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 902 903 857 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 905 906 860 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 912 919 867 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.001</italic>
###xml 931 934 883 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1002 1003 954 955 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1005 1006 957 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1011 1017 963 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 1139 1142 1076 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1164 1165 1101 1102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1167 1168 1104 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1224 1225 1158 1159 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1227 1228 1161 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1233 1239 1167 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 1251 1254 1182 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1322 1323 1253 1254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1325 1326 1256 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1331 1337 1262 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 935 939 <span type="species:ncbi:10090">mice</span>
###xml 1143 1147 <span type="species:ncbi:10090">mice</span>
###xml 1203 1207 <span type="species:ncbi:10090">mice</span>
###xml 1255 1259 <span type="species:ncbi:10090">mice</span>
C/EBPbeta+/+ [wt], C/EBPbeta-Ala217 and C/EBPbeta-/- [ko] mice received weekly IP injections of CCl4 or mineral oil (control) for 12 weeks as described in Methods. A. Representative Mallory's trichrome stain for liver fibrosis (in blue; arrowheads). All C/EBPbeta+/+ (wt) mice (n: 12) developed severe liver fibrosis. The C/EBPbeta-Ala217 (n: 12; P<0.0001) and C/EBPbeta-/- [ko] (n: 6; P<0.01) mice had either no fibrosis or only minimal liver fibrosis. B. Representative Sirius red immunohistochemistry for collagen (in red; arrowhead). Marked increase in liver collagen in a cirrhotic pattern was observed in C/EBPbeta+/+, but not in C/EBPbeta-Ala 217 or C/EBPbeta-/- [ko], mice. C. Analysis of hepatic collagen content by the Sirius red collagen-binding assay, showed a approximately2.5-fold increase in C/EBPbeta+/+ mice treated with CCl4 (n: 12), compared to C/EBPbeta-Ala217 mice treated with CCl4 (n: 12; P<0.001). C/EBPbeta-/- mice were also refractory to the induction of liver fibrosis by CCl4 (n: 6; P<0.01). D. Analysis of hepatic collagen content by the hydroxyproline assay, showed a approximately2-fold increase in C/EBPbeta+/+ mice treated with CCl4 (n: 7), compared to C/EBPbeta-Ala217 mice treated with CCl4 (n: 6; P<0.01). C/EBPbeta-/- mice were also refractory to the induction of liver fibrosis by CCl4 (n: 6; P<0.01).
###end p 18
###begin p 19
###xml 102 105 102 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier1">[4]</xref>
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Jimenez1">[19]</xref>
###xml 156 165 156 165 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</underline>
###xml 156 165 156 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1C</underline></xref>
###xml 390 393 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 405 406 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 471 480 462 471 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</underline>
###xml 471 480 462 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1C</underline></xref>
###xml 523 524 514 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 585 588 573 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 600 601 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 665 674 650 659 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1D</underline>
###xml 665 674 650 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1D</underline></xref>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
###xml 466 468 <span type="species:ncbi:10090">NS</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 654 658 <span type="species:ncbi:10090">mice</span>
###xml 660 662 <span type="species:ncbi:10090">NS</span>
The quantitative analysis of liver collagen, the major extracellular matrix protein in liver fibrosis [4], with the Sirius red collagen-binding assay [19] (Figure 1C), demonstrated that C/EBPbeta-Ala217 mice were refractory to the development of liver fibrosis after chronic exposure to the hepatotoxin. The liver collagen content increased approximately 2.5-fold from baseline in C/EBPbeta+/+ (wt) mice (P<0.001) while remaining unchanged in C/EBPbeta-Ala217 mice (NS) (Figure 1C). Similarly, chronic administration of CCl4 increased liver hydroxyproline collagen content in C/EBPbeta+/+ (wt) mice (P<0.01) while remaining unchanged in C/EBPbeta-Ala217 mice (NS) (Figure 1D).
###end p 19
###begin p 20
###xml 139 143 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 261 265 249 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722; </sup>
###xml 319 322 304 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 361 362 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 364 365 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 373 381 358 366 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</underline>
###xml 373 381 358 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1</underline></xref>
###xml 381 394 366 379 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A, B, C and D</underline>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
We have reported that by lacking the essential C/EBPbeta-PhosphoThr217, C/EBPbeta-/- HSC are also unable to survive the activation signals [10]. Thus, we postulated that C/EBPbeta-/- mice would be refractory to the induction of liver fibrosis. Indeed, C/EBPbeta-/- (ko) mice had a lower fibrotic response than C/EBPbeta+/+ mice to the chronic treatment with CCl4 (P<0.01) (Figure 1A, B, C and D).
###end p 20
###begin p 21
###xml 138 144 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 193 199 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 257 263 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 285 287 274 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 328 331 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 390 398 373 381 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</underline>
###xml 390 398 373 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g002"><underline>Figure 2</underline></xref>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
Further, the expression of the liver fibrogenic indicators such as collagen alpha 1 type 1 mRNA (newly synthesized collagen) (NM_007742 )(P<0.01), alpha-SMA mRNA (activated HSC) (NM_007392.2) (P<0.05), and TGF-beta mRNA (fibrogenic cytokine) (NM_009370.2) (P<0.01), were induced by CCl4 treatment significantly more in C/EBPbeta+/+ mice than in C/EBPbeta-Ala217 mice as measured by RT-PCR (Figure 2).
###end p 21
###begin title 22
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice expressing the RSK-inhibitory C/EBPbeta-Ala217 transgene are resistant to hepatotoxin-induced liver fibrogenesis.
###end title 22
###begin p 23
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 111 132 111 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 196 199 189 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 226 227 219 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 248 254 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 395 416 388 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 451 457 444 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 555 561 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 613 617 592 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+ </sup>
###xml 643 645 622 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 665 671 644 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 812 833 791 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 868 874 847 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 959 965 931 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 1016 1020 982 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+ </sup>
###xml 1046 1048 1012 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 1068 1074 1034 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 1215 1236 1181 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1272 1278 1238 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 1362 1368 1322 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 531 535 <span type="species:ncbi:10090">mice</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 935 939 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
###xml 1338 1342 <span type="species:ncbi:10090">mice</span>
Mice were treated with CCl4 or control mineral oil for 12 or 16 weeks and RT-PCR was performed as described in Materials and Methods. A. RT-PCR for collagen alpha1 type 1 was induced in C/EBPbeta +/+ [wt] mice treated with CCl4 for 12 or 16 weeks (P<0.01). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in Materials and Methods blocked this increase at week 16 (P<0.05). Collagen alpha1 type 1 was not increased in livers of C/EBPbeta-Ala217 mice at 12 or 16 weeks (P<0.01). B. RT-PCR for alpha-SMA was induced in C/EBPbeta +/+ [wt] mice treated with CCl4 for 12 or 16 weeks (P<0.05). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in Materials and Methods blocked this increase at week 16 (P<0.05). alpha-SMA was not increased in livers of C/EBPbeta-Ala217 mice at 12 or 16 weeks (P<0.05). C. RT-PCR for TGF-beta was induced in C/EBPbeta +/+ [wt] mice treated with CCl4 for 12 or 16 weeks (P<0.01). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in Materials and Methods, blocked this increase at week 16 (P<0.01). TGF-beta was not increased in livers of C/EBPbeta-Ala217 mice at 12 or 16 weeks (P<0.01).
###end p 23
###begin p 24
In summary, blocking phosphorylation of C/EBPbeta-Thr217 through the inhibition of RSK activity with the C/EBPbeta-Ala217 transgene or by C/EBPbeta gene knock-out decreases the fibrotic response of the liver to chronic injury.
###end p 24
###begin title 25
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice expressing the RSK-inhibitory C/EBPbeta-Ala217 transgene are resistant to hepatotoxin-induced liver inflammation
###end title 25
###begin p 26
###xml 83 87 83 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier2">[20]</xref>
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Matsuoka1">[22]</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Passino1">[23]</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-LeCouter1">[24]</xref>
###xml 685 689 685 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier3">[25]</xref>
###xml 689 693 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier4">[26]</xref>
###xml 767 770 761 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 785 786 779 780 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 831 839 825 833 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S1</underline>
###xml 831 839 825 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001372.s001"><underline>Table S1</underline></xref>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 525 531 <span type="species:ncbi:9606">humans</span>
###xml 726 730 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
Because liver inflammation, at least in part through the activation of macrophages [20]-[22] and loss of hepato-trophic factors from HSC and liver endothelial cells [23][24] is a major contributor to liver injury and liver fibrosis, we assessed the degree of liver injury and inflammation in response to the hepatotoxin. Liver injury was determined by measuring serum alanine aminotransferase (ALT) levels in mice after exposure to the hepatotoxin. Serum ALT is a sensitive and specific indicator of hepatocellular injury in humans and animals, and it is the standard clinical test used by the U.S. Food and Drug Administration to ascertain hepatotoxicity of herbal products and drugs [25][26]. We found that C/EBPbeta-Ala217 mice had less liver injury than C/EBPbeta+/+ mice after CCl4 treatment, judging by the ALT serum levels (Table S1).
###end p 26
###begin p 27
###xml 285 286 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 335 338 329 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 363 364 357 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 366 373 360 367 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</underline>
###xml 366 373 360 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001372-t001"><underline>Table 1</underline></xref>
###xml 99 114 <span type="species:ncbi:10090">transgenic mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
Using a microarray assay to assess expression of 66 inflammation genes in the liver of control and transgenic mice, we found that the expression of 21 inflammation genes was decreased, while the expression of other 45 inflammation genes was unchanged in C/EBPbeta-Ala217 mice after CCl4-induced liver injury, when compared to C/EBPbeta+/+ animals treated with CCl4 (Table 1).
###end p 27
###begin title 28
###xml 72 73 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Decreased Inflammation in the Livers of C/EBPbeta- Ala217 mice after CCl4 treatment.
###end title 28
###begin p 29
###xml 47 48 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
Animals received either mineral oil [MO] or CCl4. Thirty hours after a single intraperitoneal dose of CCl4,
###end p 29
###begin p 30
###xml 18 19 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 114 117 108 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 124 125 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
C/EBPbeta Ala217 (n: 9) mice had a markedly decreased liver expression of inflammatory genes compared to C/EBPbeta+/+ mice (n: 9). A panel of 86 inflammatory genes were evaluated by RT-QPCR; 21 of these genes were significantly reduced (P<0.05 for all 21 genes).
###end p 30
###begin p 31
###xml 265 268 259 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 275 284 269 278 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</underline>
###xml 275 284 269 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g003"><underline>Figure 3A</underline></xref>
###xml 457 466 448 457 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</underline>
###xml 457 466 448 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g003"><underline>Figure 3B</underline></xref>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
These data suggest that partial resistance to liver injury and inflammation may contribute to the prevention of liver fibrosis in C/EBPbeta-Ala217 mice. A decreased inflammatory response, mediated at least in part by monocytes/macrophages in the livers of C/EBPbeta+/+ mice (Figure 3A), may be responsible for the decreased liver injury in C/EBPbeta-Ala217 mice, since RSK inhibition also affected the recruitment of CD-68+ inflammatory cells to the liver (Figure 3B).
###end p 31
###begin title 32
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice expressing the RSK-inhibitory C/EBPbeta-Ala217 transgene are resistant to hepatotoxin-induced liver inflammation.
###end title 32
###begin p 33
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 80 101 80 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 230 233 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 260 261 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 430 450 427 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Material and methods</xref>
###xml 843 846 834 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 881 882 872 873 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 800 804 <span type="species:ncbi:10090">mice</span>
###xml 852 856 <span type="species:ncbi:10090">mice</span>
Mice were treated with CCl4 or control mineral oil for 16 weeks as described in Materials and Methods. A. Activated monocytes/macrophages, identified by confocal microscopy for CD-68 (green), were increased in livers of C/EBPbeta +/+ [wt] mice treated with CCl4 for 16 weeks (middle panels). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in Material and methods, blocked the monocytes/macrophage inflammatory reaction at week 16 (lower panels). Nuclei are identified with TO-PRO-3 (blue). Only background staining was observed when omitting the first antibody. Microscopy shown is representative of six animals in each group. B. Activated monocytes/macrophages, were not increased in livers of C/EBPbeta-Ala217 mice as much as in the livers of C/EBPbeta +/+ [wt] mice after treatment with CCl4 for 16 weeks (lower panel). Microscopy shown is representative of six animals in each group.
###end p 33
###begin p 34
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Koop1">[27]</xref>
###xml 286 287 283 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 314 317 308 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 345 355 336 346 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S2A</underline>
###xml 345 355 336 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001372.s003"><underline>Figure S2A</underline></xref>
###xml 446 449 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 509 519 494 504 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S2B</underline>
###xml 509 519 494 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001372.s003"><underline>Figure S2B</underline></xref>
###xml 678 688 656 666 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S2C</underline>
###xml 678 688 656 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001372.s003"><underline>Figure S2C</underline></xref>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
Given that CCl4 is metabolized by the cythocrome-P-450 2E-1(Cyp-2E-1) (ABH07947) to form a free radical hepatotoxic metabolite [27], we evaluated the possibility that C/EBPbeta-Ala217 affects Cyp-2E1 expression and/or activity. The Cyp-2E1 mRNA expression was similarly inhibited by CCl4 in the livers of C/EBPbeta+/+ and C/EBPbeta-Ala217 mice (Figure S2A). In addition, the Cyp-2E-1 protein expression was also similar in the livers of C/EBPbeta+/+ and C/EBPbeta-Ala217 mice after the hepatotoxin treatment (Figure S2B). Moreover, the Cyp-2E1 activity as measured in a cell-free system was unaltered by a RSK-inhibitory C/EBPbeta-Ala217 peptide, even at microM concentrations (Figure S2C).
###end p 34
###begin p 35
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 195 196 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
These results indicate that the protective effects of the RSK-inhibitory transgene in CCl4 -induced liver injury and fibrosis are not due to the spurious blockade of the production of a toxic CCl4 metabolite.
###end p 35
###begin title 36
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice expressing the RSK-inhibitory C/EBPbeta-Ala217 transgene are resistant to hepatotoxin-induced HSC activation and proliferation
###end title 36
###begin p 37
###xml 179 182 179 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Lee1">[6]</xref>
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Friedman1">[7]</xref>
###xml 273 276 273 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-AnkomaSey1">[9]</xref>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
Quiescent HSC produce negligible amounts of ECM, but after their activation, these cells develop a myofibroblastic phenotype, proliferate, and become the main contributors of ECM [5][6]. Because this step is required for the development of liver fibrosis and cirrhosis [7]-[9], we analyzed the activation and proliferation of HSC in the livers of mice chronically exposed to the hepatotoxin.
###end p 37
###begin p 38
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 53 56 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 187 190 180 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 190 193 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Lee1">[6]</xref>
###xml 195 204 188 197 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A</underline>
###xml 195 204 188 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4A</underline></xref>
###xml 366 370 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bravo1">[28]</xref>
###xml 372 381 361 370 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4B</underline>
###xml 372 381 361 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4B</underline></xref>
###xml 494 495 480 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 507 522 493 508 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A and B</underline>
###xml 507 522 493 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4A and B</underline></xref>
###xml 546 547 532 533 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 652 655 632 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 732 741 712 721 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4B</underline>
###xml 732 741 712 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4B</underline></xref>
###xml 761 762 741 742 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 837 840 811 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 919 934 890 905 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A and B</underline>
###xml 919 934 890 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4A and B</underline></xref>
###xml 1000 1002 971 973 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</underline>
###xml 999 1003 970 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[<underline>10</underline>]</xref>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
###xml 656 660 <span type="species:ncbi:10090">mice</span>
###xml 841 845 <span type="species:ncbi:10090">mice</span>
###xml 875 879 <span type="species:ncbi:10090">mice</span>
As expected, chronic CCl4 administration to C/EBPbeta+/+ (wt) mice, induced marked activation of HSC, as indicated by the positive immunofluorescence for alpha-SMA within the scar tissue [5][6] (Figure 4A), and proliferation of HSC, as indicated by the presence of proliferating cell nuclear antigen (PCNA; DNA polymerase delta auxiliary protein), an S-phase marker [28] (Figure 4B). By contrast, C/EBPbeta-Ala217 mice were refractory to the induction of HSC activation and proliferation by CCl4 treatment (Figure 4A and B). Moreover, chronic CCl4 treatment induced the apoptotic cascade in HSC in the livers of C/EBPbeta-Ala217 mice, but not C/EBPbeta+/+ mice, as determined by the presence of active caspase 3 immunofluorescence (Figure 4B). After chronic CCl4 administration, C/EBPbeta was phosphorylated on Thr217 in HSC of C/EBPbeta+/+ mice, but not in C/EBPbeta-Ala217 mice, as determined by confocal microscopy (Figure 4A and B), using specific antibodies against this phosphorylated epitope [10].
###end p 38
###begin title 39
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice expressing the RSK-inhibitory C/EBPbeta-Ala217 transgene are refractory to hepatic stellate cell activation and proliferation.
###end title 39
###begin p 40
###xml 17 19 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 74 95 74 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and methods</xref>
###xml 273 276 259 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 330 331 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 650 653 623 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 680 681 653 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 787 788 757 758 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
###xml 766 770 <span type="species:ncbi:10090">mice</span>
Mice received CCl4 or mineral oil injections for 12 weeks as described in Materials and methods. A. Activated stellate cells, identified by confocal microscopy for alpha-smooth muscle actin (alpha-SMA; red), displayed C/EBPbeta-PhosphoThr217 (green) in livers of C/EBPbeta +/+ [wt], but not C/EBPbeta-Ala217, mice treated with CCl4. Colocalization of alpha-SMA and C/EBPbeta-PhosphoThr217 is shown in yellow (merge). Nuclei are identified with TO-PRO-3 (blue). Only background staining was observed when omitting the first antibody. B. Proliferating cell nuclear antigen (PCNA; red) was present in activated stellate cells only in livers of C/EBPbeta+/+ [wt] mice treated with CCl4, while active caspase 3 (green) was found in HSC only in livers of C/EBPbeta-Ala217 mice treated with CCl4. Nuclei are identified with TO-PRO-3 (blue).
###end p 40
###begin p 41
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 329 332 323 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 424 433 412 421 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</underline>
###xml 424 433 412 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5A</underline></xref>
###xml 560 563 545 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 563 567 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 567 571 552 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bonni1">[11]</xref>
###xml 714 723 696 705 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5B</underline>
###xml 714 723 696 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5B</underline></xref>
###xml 877 886 859 868 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5B</underline>
###xml 877 886 859 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5B</underline></xref>
###xml 354 358 <span type="species:ncbi:10090">mice</span>
Because the mixed cell population of the liver limits the evaluation of signaling cascades in a specific cell type, we studied the fibrogenic pathway in purified HSC. After chronic CCl4 or control mineral oil administration, we analyzed proteins associated with C/EBPbeta, immunopurified from HSC, freshly isolated from C/EBPbeta+/+ and C/EBPbeta-Ala217 mice. C/EBPbeta-Ala217 binding to, and blocking, RSK phosphorylation (Figure 5A) results in decreased phosphorylation of C/EBPbeta on Thr217, and presumably, other target survival proteins by activated RSK [5][10][11]. The Ac-KAla217VD-CHO or C/EBPbeta216-253-Ala217 (0.25 nM) peptides inhibited RSK activity in a cell-free system, suggesting a direct effect (Figure 5B). The Ac-KThr217VD-CHO wt peptide also inhibited RSK, probably, because it binds to the kinase but cannot be phosphorylated by RSK given its small size (Figure 5B).
###end p 41
###begin title 42
C/EBPbeta-Ala217 inhibits RSK activation in hepatic stellate cells.
###end title 42
###begin p 43
###xml 149 155 149 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g001">Fig. 1</xref>
###xml 532 539 523 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 976 979 946 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 961 966 <span type="species:ncbi:9606">human</span>
A. A phospho-RSK immunoblot was performed on RSK immunoprecipitates from protein lysates of purified HSC in an experiment conducted as described in (Fig. 1). Phosphorylated RSK (RSKp380) was decreased in HSC isolated from C/EBPbeta-Ala217 mice. C/EBPbeta and RSK were similar in the different experimental groups. beta-Actin was used as an internal control for the immunoprecipitations. Results from triplicate samples of three independent experiments are shown. B. RSK activity was determined in a cell-free system as described in Methods. Recombinant RSK was activated with ATP (125 microM) in the presence or absence of Ac-KThrVD-CHO (200 microM), Ac-KAlaVD-CHO (200 microM), or C/EBPbeta216-253-Ala217 (0.25 nM) peptides. Staurosporine was used as a control inhibitor (0.01 nM). All C/EBPbeta peptides inhibited RSK activity to a similar extent as staurosporine (P<0.01). Results from triplicate samples of two independent experiments are shown. C. Primary human C/EBPbeta+/+ HSC were transfected with vectors (1 microg each) expressing green fluorescent protein with control wt RSK (GFP), a dominant negative RSK mutant, or C/EBPbeta-Ala217. Transfected HSC were selected by sorting for GFP, and cell lysates were immunoprecipitated with C/EBPbeta specific antibodies. C/EBPbeta-PhosphoThr217 (C/EBPbetap217), and caspase 8 immunoblots were performed in C/EBPbeta immunoprecipitates. Dominant negative RSK or C/EPBbeta-Ala217 prevented C/EPBbeta phosphorylation and stimulated the association of unphosphorylated C/EBPbeta with active caspase 8. beta-Actin was used as an internal control for the immunoprecipitations. Results from triplicate samples of three independent experiments are shown.
###end p 43
###begin title 44
C/EBPbeta-Ala217 transgene and unphosphorylated C/EBPbeta-Thr217 are associated with active caspase 8 and death receptor complex II proteins in HSC
###end title 44
###begin p 45
###xml 130 131 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 206 215 200 209 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</underline>
###xml 206 215 200 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6A</underline></xref>
###xml 306 315 297 306 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</underline>
###xml 306 315 297 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6A</underline></xref>
###xml 379 388 367 376 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</underline>
###xml 379 388 367 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5A</underline></xref>
###xml 420 423 405 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 446 447 431 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 588 597 570 579 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</underline>
###xml 588 597 570 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6A</underline></xref>
###xml 794 803 770 779 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</underline>
###xml 794 803 770 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5A</underline></xref>
###xml 1023 1024 993 994 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1041 1050 1011 1020 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</underline>
###xml 1041 1050 1011 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6A</underline></xref>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
###xml 663 667 <span type="species:ncbi:10090">mice</span>
###xml 1001 1005 <span type="species:ncbi:10090">mice</span>
Unexpectedly, we found that C/EBPbeta-Ala217 was present with active caspase 8 in HSC from C/EBPbeta-Ala217 mice after chronic CCl4 administration and, to a lesser extent, after mineral oil administration (Figure 6A). In contrast, the association between inactive procaspase 8 and C/EBPbeta-PhosphoThr217 (Figure 6A), as well as that between C/EBPbeta and activated phospho-RSK (Figure 5A), increased in HSC of C/EBPbeta+/+ mice after chronic CCl4 administration. Reciprocal immunoprecipitation with caspase 8 antibodies confirmed the presence of C/EBPbeta- Ala217 with active caspase 8 (Figure 6A). RSK phosphorylation was inhibited in HSC from C/EBPbeta-Ala217 mice, indicating that C/EBPbeta-Ala217 not only associates with RSK but that it also decreases its phosphorylation and activation (Figure 5A). The hypothesis that inhibition of RSK by nonphosphorylatable C/EBPbeta-Ala217 is critical for caspase 8 activation is supported by the increased caspase 8 activation in HSC from C/EBPbeta-Ala217 mice after chronic CCl4 administration (Figure 6A).
###end p 45
###begin title 46
C/EBPbeta-Ala217 associates with active caspase 8 in hepatic stellate cells.
###end title 46
###begin p 47
###xml 120 127 117 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005">Fig 5 A</xref>
###xml 347 348 332 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 781 790 754 763 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5C</underline>
###xml 781 790 754 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5C</underline></xref>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
A. A caspase 8 immunoblot was performed on C/EBPbeta immunoprecipitates from protein lysates from samples described in (Fig 5 A). The association between C/EBPbeta-Ala217 with active caspase 8 was increased in HSC isolated from C/EBPbeta-Ala217 mice. Phosphorylated C/EBPbeta-Thr217 was decreased in HSC from C/EBPbeta-Ala217 mice treated with CCl4. C/EBPbeta and RSK were similar in the different experimental groups. beta-Actin was used as an internal control for the immunoprecipitations. B. Reciprocal caspase 8 immunoprecipitation of experiment described in (A) confirmed the association of C/EBPbeta-Ala217 with active caspase 8. beta-Actin was used as an internal control for the immunoprecipitations. C. Reciprocal caspase 8 immunoprecipitation of experiment described in (Figure 5C), confirmed the association of C/EBPbeta-Ala217 with active caspase 8. beta-Actin was used as an internal control for the immunoprecipitations.
###end p 47
###begin p 48
###xml 116 119 113 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 461 464 455 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-AnkomaSey1">[9]</xref>
###xml 509 513 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 101 106 <span type="species:ncbi:9606">human</span>
Next, we studied whether blocking RSK activity results in activation of caspase 8. Activated primary human C/EBPbeta+/+ HSC were transfected with vectors expressing green fluorescent protein with a control wt RSK (GFP), to facilitate cell sorting, with a dominant negative RSK mutant, or with the RSK-inhibitory dominant negative C/EBPbeta-Ala217. The HSC were activated on a collagen type 1 matrix, a condition that recapitulates the activation of HSC in vivo [9], and identified by their expression of GFAP [10].
###end p 48
###begin p 49
###xml 265 274 256 265 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5C</underline>
###xml 265 274 256 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5C</underline></xref>
###xml 383 386 371 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 441 445 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
###xml 345 350 <span type="species:ncbi:9606">human</span>
As expected, C/EBPbeta-PhosphoThr266 (identical to mouse phosphoacceptor Thr217) was markedly decreased in activated human HSC expressing either the RSK mutant or C/EBPbeta-Ala217. Moreover, we found that unphosphorylated C/EBPbeta was associated active caspase 8 (Figure 5C). The RSK phosphoacceptor site in C/EBPbeta is identical in mouse and human, it is evolutionarily conserved [5], and essential for HSC survival upon their activation [10].
###end p 49
###begin p 50
###xml 98 107 95 104 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5C</underline>
###xml 98 107 95 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5C</underline></xref>
###xml 293 302 284 293 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5C</underline>
###xml 293 302 284 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5C</underline></xref>
###xml 331 335 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 479 495 467 483 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6 B and C</underline>
###xml 479 495 467 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6 B and C</underline></xref>
###xml 845 849 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Micheau1">[29]</xref>
###xml 851 870 830 849 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7A, B, and C</underline>
###xml 851 870 830 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g007"><underline>Figure 7A, B, and C</underline></xref>
###xml 972 980 948 956 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7</underline>
###xml 972 980 948 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g007"><underline>Figure 7</underline></xref>
###xml 980 994 956 970 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and Figure S3</underline>
###xml 980 994 956 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001372.s004"><underline> and Figure S3</underline></xref>
###xml 1169 1171 1145 1147 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">30</underline>
###xml 1168 1172 1144 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Leite1">[<underline>30</underline>]</xref>
###xml 1172 1176 1148 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Zhang1">[31]</xref>
C/EBPbeta-Ala266 associated with active caspase 8, in cells expressing the dominant negative RSK (Figure 5C), which prevents C/EBPbeta phosphorylation on Thr266 by RSK. In contrast, in the control cells expressing GFP and RSK wt, C/EBPbeta was phosphorylated and associated with procaspase 8 (Figure 5C), as we reported previously [10]. Reciprocal immunoprecipitation with caspase 8 specific antibodies confirmed the presence of unphosphorylated C/EBPbeta with active caspase 8 (Figure 6 B and C). After blocking the RSK-C/EBPbeta phosphorylation cascade in activated HSC, with either an ERK1/2 inhibitor or a cell permeant Ac-KAla217VD-CHO peptide, which contains the mutated C/EBPbeta-Ala217 phosphoacceptor, unphosphorylated C/EBPbeta became associated with other members of the death receptor complex II, such as TNFR1, TRAF2, TRADD and RIP [29] (Figure 7A, B, and C). These associations were identified in C/EBPbeta, TNFR1, TRAF2, TRADD and RIP immunoprecipitations (Figure 7 and Figure S3). The Ac-KAla217VD-CHO peptide is cell permeant due to its N-terminus acetyl group, as it has been documented for other peptides used as substrate or inhibitors of caspases [30][31].
###end p 50
###begin title 51
RSK inhibition induces the association of C/EBPbeta with active caspase 8, TNFR1, TRAF2, TRADD and RIP.
###end title 51
###begin p 52
###xml 628 629 599 600 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 665 686 636 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1067 1068 1020 1021 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1104 1125 1057 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1504 1505 1445 1446 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1541 1562 1482 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 111 116 <span type="species:ncbi:9606">human</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 1046 1050 <span type="species:ncbi:10090">mice</span>
###xml 1483 1487 <span type="species:ncbi:10090">mice</span>
A. TRADD, C/EBPbeta, RIP and caspase 8 immunoblots were performed on C/EBPbeta immunoprecipitates from primary human HSC treated with an ERK1/2 inhibitor (10 microM) or the cell permeant Ac-KA217VD-CHO peptide (200 microM). Blocking the phosphorylation of C/EBPbeta by RSK with the ERK1/2 inhibitor or the cell permeant Ac-KA217VD-CHO (KAVD) peptide, increased the association between C/EBPbeta, active caspase 8, TRADD and RIP. beta-Actin was used as an internal control for the immunoprecipitations. B. TNFR1 and C/EBPbeta immunoblots were performed on C/EBPbeta immunoprecipitates from HSC isolated from mice treated with CCl4 for 12 or 16 weeks as described in Materials and Methods. Blocking the phosphorylation of C/EBPbeta by RSK with C/EBPbeta-Ala217 transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between C/EBPbeta and TNFR1. beta-Actin was used as an internal control for the immunoprecipitations. C. TRAF2 and C/EBPbeta immunoblots were performed on C/EBPbeta immunoprecipitates from HSC isolated from mice treated with CCl4 for 12 or 16 weeks as described in Materials and Methods. Blocking the phosphorylation of C/EBPbeta by RSK with C/EBPbeta-Ala217 transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between C/EBPbeta and TRAF2. beta-Actin was used as an internal control for the immunoprecipitations. D. Cytochrome C and Apaf1 immunoblots were performed on cytochrome C immunoprecipitates in livers from mice treated with CCl4 for 12 or 16 weeks as described in Materials and Methods. Blocking the phosphorylation of C/EBPbeta by RSK with C/EBPbeta-Ala217 transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between cytochrome C and Apaf1. beta-Actin was used as an internal control for the immunoprecipitations.
###end p 52
###begin title 53
A cell-permeant C/EBPbeta-Ala217 peptide stimulates active caspase 8 and cell death in collagen type 1-induced activation of cultured HSC
###end title 53
###begin p 54
###xml 201 210 198 207 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7D</underline>
###xml 201 210 198 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g007"><underline>Figure 7D</underline></xref>
###xml 318 322 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Spierings1">[32]</xref>
###xml 696 705 687 696 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S4</underline>
###xml 696 705 687 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001372.s005"><underline>Figure S4</underline></xref>
###xml 1014 1015 999 1000 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1142 1143 1124 1125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1167 1169 1149 1151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 1302 1305 1278 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 647 652 <span type="species:ncbi:10090">mouse</span>
###xml 677 682 <span type="species:ncbi:10090">mouse</span>
###xml 982 997 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1106 1121 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1257 1272 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1306 1310 <span type="species:ncbi:10090">mice</span>
We corroborated the activation of caspase 8 in HSC, under conditions that prevented phosphorylation of C/EBPbeta, as described above, by demonstrating the association between cytochrome C with Apaf-1 (Figure 7D), which reflects a downstream amplification effect of active caspase 8 on mitochondrial apoptotic pathways [32]. The reciprocal analysis could not be performed since Apaf-1 antibodies are not suitable for immunoprecipitation. Moreover, inhibition of the RSK-C/EBPbeta phosphorylation cascade with the cell permeant C/EBPbeta-Ala217 peptide, Ac-KAla217VD-CHO induced expression of the apoptosis effector caspase 3 in cultured, activated mouse HSC, but not in primary mouse hepatocytes (Figure S4). These findings suggest a selective induction of apoptotic pathways by C/EBPbeta-Ala217 peptides in cultured activated HSC but not in cultured primary hepatocytes. This conclusion is supported by the apoptotic changes in activated HSC but not hepatocytes of C/EBPbeta-Ala217 transgenic mice treated with CCl4, and by the lack of apoptosis of normal quiescent HSC and hepatocytes of C/EBPbeta-Ala217 transgenic mice not treated with CCl4. In addition, after CCl4 treatment, hepatocyte injury and hepatic inflammation are decreased in C/EBPbeta-Ala217 transgenic mice compared to control C/EBPbeta+/+ mice, arguing for a protective rather than an apoptotic effect on hepatocytes.
###end p 54
###begin p 55
###xml 315 317 306 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 318 327 309 318 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8A</underline>
###xml 318 327 309 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8A</underline></xref>
###xml 472 481 463 472 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8B</underline>
###xml 472 481 463 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8B</underline></xref>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
Our findings in cell-free, cellular and animal models strongly support the main hypothesis, and suggest a novel, physiological role for unphosphorylated C/EBPbeta on caspase 8 activation. Indeed, we found that caspase 8 activation is stimulated by C/EBPbeta-Ala217 in HSC from C/EBPbeta-Ala217 mice treated with CCl4 (Figure 8A). In addition, we determined that the peptide enhanced the activity of recombinant caspase 8 in a cell-free system at picomolar concentrations (Figure 8B). To our knowledge, the C/EBPbeta-Ala217 peptides are the first reported compounds to directly enhance caspase 8 activation (G Salvesen, personal communication).
###end p 55
###begin title 56
###xml 100 101 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
The RSK-inhibitory peptide blocks hepatic stellate cell activation and liver fibrosis induced by CCl4.
###end title 56
###begin p 57
###xml 77 81 74 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+ </sup>
###xml 141 142 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 226 227 217 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 378 385 369 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 604 610 595 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 691 693 682 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 724 731 715 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 817 838 801 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and methods</xref>
###xml 1038 1059 1015 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and methods</xref>
###xml 1178 1181 1152 1155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1243 1244 1217 1218 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1281 1282 1255 1256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1531 1532 1497 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1548 1549 1514 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1570 1571 1536 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1668 1669 1634 1635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1690 1691 1656 1657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1756 1762 1722 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 1903 1906 1854 1857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1928 1929 1879 1880 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1931 1932 1882 1883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1949 1950 1900 1901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1971 1972 1922 1923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2056 2057 2007 2008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2074 2075 2025 2026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2093 2099 2044 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 2225 2228 2173 2176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2250 2251 2198 2199 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 2267 2268 2215 2216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2285 2286 2233 2234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2307 2308 2255 2256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2392 2393 2340 2341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2410 2411 2358 2359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2429 2435 2377 2383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 1187 1191 <span type="species:ncbi:10090">mice</span>
###xml 1525 1529 <span type="species:ncbi:10090">mice</span>
###xml 1627 1631 <span type="species:ncbi:10090">mice</span>
###xml 1907 1911 <span type="species:ncbi:10090">mice</span>
###xml 2229 2233 <span type="species:ncbi:10090">mice</span>
A Caspase 8 activity was measured in lysates from HSC isolated from C/EBPbeta+/+ [wt] and C/EBPbeta-Ala217 mice untreated or treated with CCl4 for 24 hr. Caspase activity was increased in C/EBPbeta-Ala217 mice treated with CCl4. Results from triplicate samples of two independent experiments are shown. B. Caspase activation in a cell-free system was determined as described in Methods. The Ac-KAla217VD-CHO peptide enhanced the activation of caspase 8 at picomolar concentrations. Baseline caspase 8 activity was 3.8 U (100%). Results from triplicate samples of three independent experiments are shown (P<0.01 for the Ac-KAla217VD-CHO peptide). C. Animals received a single injection of CCl4 or mineral oil as described in Methods. alpha-SMA (red) and C/EBPbeta-PhosphoThr217 (green) were identified as described in Materials and methods. Treatment with the cell permeant Ac-KAla217VD-CHO peptide blocked the expression of alpha-SMA and C/EBPbeta-PhosphoThr217. D. PCNA (red) and active caspase 3 (green) were identified as described in Materials and methods. Treatment with the Ac-KAla217VD-CHO peptide blocked the expression of PCNA and induced active caspase 3. E. C/EBPbeta+/+ (wt) mice with severe liver fibrosis after treatment with CCl4 for 8 weeks, while continuing on CCl4, received the RSK inhibitory peptide (5 microg IP, three times/week, for week 9 followed by 1 microg IP, three times/week for weeks 10-12 or 10-16). These are representative Mallory's trichrome stain for liver fibrosis (in blue). All control mice (n: 8 at 8-weeks; n: 8 at 12-weeks; and n: 8 at 16-weeks) developed severe liver fibrosis, while mice receiving the RSK-inbitory peptide (n: 8 at 12-weeks; and n: 8 at 16-weeks) had no fibrosis or only minimal liver fibrosis (P<0.01). F. Analysis of hepatic collagen content by the Sirius red collagen-binding assay showed a approximately2.5 to 3-fold increase in C/EBPbeta+/+ mice treated with CCl4 (n: 8 for 8 weeks; n: 8 for 12 weeks and n: 8 for the 16 weeks), compared to animals also receiving the RSK-inbitory peptide (n: 6 for 12weeks; n: 8 for 16 weeks; P<0.01). G. Analysis of hepatic collagen content by the hydroxyproline assay, showed a 2.2-, 3.5- and 5.3-fold increase in C/EBPbeta+/+ mice treated with CCl4, respectively (n: 8 for 8 weeks; n: 7 for 12 weeks and n: 7 for the 16 weeks), compared to animals also receiving the RSK-inbitory peptide (n: 6 for 12weeks; n: 8 for 16 weeks; P<0.01).
###end p 57
###begin p 58
These experiments provided a strong proof-of-principle that RSK activation mediates the signaling required for liver inflammation and liver fibrosis.
###end p 58
###begin title 59
A cell-permeant C/EBPbeta-Ala217 peptide stimulates cell death in hepatotoxin-induced activation of HSC
###end title 59
###begin p 60
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 301 305 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Rudolph1">[16]</xref>
###xml 364 366 364 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 378 381 375 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 445 449 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Rudolph1">[16]</xref>
###xml 560 564 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 786 787 771 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 967 982 948 963 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C and D</underline>
###xml 967 982 948 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8C and D</underline></xref>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
Because in preliminary studies the cell permeant tetrapeptide Ac-KAla217VD-CHO was effective in inducing apoptosis of cultured activated HSC [10], we studied whether this peptide would also be effective in inducing apoptosis of activated HSC in a physiologically relevant animal model of liver injury [10][16]. To activate HSC, we administered a single dose of CCl4 to C/EBPbeta+/+ (wt) mice, while control mice received the mineral oil vehicle [16]. Six hours later, animals received an intraperitoneal injection of the cell permeant Ac-KAla217VD-CHO peptide [10] (100 microg) or saline vehicle (100 microl). In preliminary studies, we found that 1-100 microg of peptide dose provided adequate bioavailability (M B, unpublished observations). Animals were sacrificed at 24 h. Acute CCl4 administration induced both activation and proliferation of HSC (among other hepatic cells), judging by the expression of alphaSMA and PCNA, as determined by confocal microscopy (Figure 8C and D).
###end p 60
###begin p 61
###xml 128 143 128 143 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C and D</underline>
###xml 128 143 128 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8C and D</underline></xref>
###xml 410 411 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 413 422 407 416 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C</underline>
###xml 413 422 407 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8C</underline></xref>
###xml 722 732 710 720 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8 D</underline>
###xml 722 732 710 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8 D</underline></xref>
###xml 260 275 <span type="species:ncbi:10090">transgenic mice</span>
###xml 573 588 <span type="species:ncbi:10090">transgenic mice</span>
HSC activation and proliferation were blocked by treatment with the Ac-KAla217VD-CHO peptide, but not by treatment with saline (Figure 8C and D). Similarly to our findings of RSK inhibition in cell-free, cultured primary stellate cells and in C/EBPbeta-Ala217 transgenic mice, the Ac-KAla217VD-CHO peptide prevented the phosphorylation of C/EBPbeta on Thr217 in HSC activated by the liver injury induced by CCl4 (Figure 8C). Further, and in agreement to our findings of the increased caspase 8 activation in cell-free, cultured primary stellate cells and in C/EBPbeta-A217 transgenic mice, the Ac-KAla217VD-CHO peptide stimulated the apoptotic pathway of C/EBPbeta wt HSC as indicated by the presence of active caspase 3 (Figure 8 D).
###end p 61
###begin title 62
A cell-permeant C/EBPbeta-Ala217 peptide inhibits progression and stimulates regression of hepatotoxin-induced liver fibrosis
###end title 62
###begin p 63
###xml 122 125 122 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chung1">[3]</xref>
###xml 125 128 125 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier1">[4]</xref>
###xml 128 131 128 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bataller1">[8]</xref>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Iredale1">[33]</xref>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Friedman3">[34]</xref>
Activation of stellate cells is responsible for the development of liver fibrosis in chronic liver diseases of all causes [3][4][8], and remarkably, HSC clearance by apoptosis may allow recovery from liver injury and reversal of liver fibrosis [33][34].
###end p 63
###begin p 64
###xml 122 124 122 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
Given the effective blocking by the RSK-inhibitory peptide of molecular pathways leading to liver fibrosis in an acute CCl4 model of liver injury and fibrogenesis, we asked whether these effects would occur in a model of established liver fibrosis due to chronic liver injury, reproducing the disease state of patients with severe liver injury and fibrosis.
###end p 64
###begin p 65
###xml 20 23 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 76 77 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 341 342 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 434 435 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 545 546 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 651 660 640 649 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8E</underline>
###xml 651 660 640 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8E</underline></xref>
###xml 687 696 676 685 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S5</underline>
###xml 717 718 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 947 948 936 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 955 959 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Jimenez1">[19]</xref>
###xml 961 970 950 959 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8F</underline>
###xml 961 970 950 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8F</underline></xref>
###xml 1039 1048 1028 1037 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8G</underline>
###xml 1039 1048 1028 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8G</underline></xref>
###xml 1106 1109 1092 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1131 1132 1117 1118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1171 1172 1157 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1189 1190 1175 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1211 1212 1197 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1296 1297 1282 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1315 1316 1301 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1334 1335 1320 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
###xml 711 715 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
Therefore, C/EBPbeta+/+ mice with severe liver fibrosis, after receiving CCl4 for 8 weeks, were treated with the RSK inhibitory peptide for an additional 4 or 8 weeks (5 microg IP, three times/week, for week 9, followed by 1 microg IP, three times/week for weeks 10-12 or 10-16), while continuing to induce liver injury and fibrosis with CCl4. Treatment of animals with liver fibrosis with the peptide, while continuing to receive CCl4, prevented the progression and induced regression of liver fibrosis compared to control mice treated with CCl4. At week-12 or week-16, there was a marked regression of liver fibrosis judging by the trichrome stain (Figure 8E) and Sirius red staining (Figure S5). All control mice (n: 22) had severe liver fibrosis, while all mice that received the RSK-inhibitory peptide had minimal or no liver fibrosis. We confirmed these findings by quantitative analysis of liver collagen with the Sirius red binding assay (P<0.01) [19] (Figure 8F). Analysis of hepatic collagen content by the hydroxyproline assay (Figure 8G), showed a 2.2-, 3.5-, and 5.3-fold increase in C/EBPbeta+/+ mice treated with CCl4 for 8, 12 and 16 weeks, respectively (n: 8 for 8 weeks; n: 7 for 12 weeks and n: 7 for the 16 weeks), compared to animals treated with the RSK-inhibitory peptide (n: 6 for 12 weeks; n: 8 for 16 weeks; P<0.01).
###end p 65
###begin p 66
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 165 168 159 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 215 216 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 249 251 243 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4,</sub>
###xml 358 359 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 399 400 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 449 450 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 458 477 441 460 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2A, B, and C</underline>
###xml 458 477 441 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g002"><underline>Figure 2A, B, and C</underline></xref>
###xml 543 552 526 535 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</underline>
###xml 543 552 526 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g003"><underline>Figure 3A</underline></xref>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
In agreement with the results observed after CCl4 treatment in mice expressing the C/EBPbeta-Ala217 transgene, treatment with the RSK-inhibitory peptide of C/EBPbeta+/+ mice with severe liver fibrosis induced by CCl4, while continuing to receive CCl4, reduced the following: i) expression of liver fibrogenic indicators such as collagen alpha 1 type 1 mRNA (P<0.05), alpha-SMA mRNA (activated HSC) (P<0.05), and TGF-beta mRNA (fibrogenic cytokine) (P<0.01) (Figure 2A, B, and C); and ii) recruitment of CD-68+ inflammatory cells to the liver (Figure 3A).
###end p 66
###begin title 67
###xml 83 88 <span type="species:ncbi:9606">human</span>
Increased expression of active RSK and C/EBPbeta-PhosphoThr266 in activated HSC of human liver fibrosis
###end title 67
###begin p 68
###xml 106 109 103 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 164 168 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 304 308 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Nakajima1">[15]</xref>
###xml 402 406 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
###xml 68 73 <span type="species:ncbi:9606">human</span>
The RSK phosphoacceptor site in C/EBPbeta is identical in mouse and human, it is evolutionarily conserved [5], and necessary for HSC survival upon their activation [10]. The RSK pathway may be critical for HSC activation induced by liver injury, because expression of a catalytically inactive mutant RSK [15], blocked proliferation and survival of cultured HSC upon their activation by collagen type 1 [10].
###end p 68
###begin p 69
###xml 424 445 419 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and methods</xref>
###xml 937 941 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 943 959 930 946 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9 A and B</underline>
###xml 943 959 930 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g009"><underline>Figure 9 A and B</underline></xref>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 217 222 <span type="species:ncbi:10090">mouse</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
###xml 336 347 <span type="species:ncbi:11103">hepatitis C</span>
###xml 468 479 <span type="species:ncbi:11103">hepatitis C</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 641 646 <span type="species:ncbi:9606">human</span>
###xml 752 760 <span type="species:ncbi:9606">patients</span>
To assess the relevance to human liver fibrosis of the cellular and animal models of liver fibrosis, we analyzed, in preliminary studies, the role of activated RSK and phosphorylated C/EBPbeta on Thr266 (identical to mouse Thr217 phosphoacceptor) as possible mechanisms leading to increased liver fibrosis in four patients with chronic hepatitis C viral infection that resulted in severe liver fibrosis (53+/-17 years) (see Materials and methods). Liver biopsies from hepatitis C patients afflicted with severe liver fibrosis (METAVIR scores of 3 or 4) displayed a high level expression of both active, phosphorylated RSK and phosphorylated human C/EBPbeta on Thr266 in activated HSC within the fibrous tissue, compared with samples from three control patients (60+/-13 years) as identified by confocal scanning microscopy with specific antibodies against RSK-PhosphoSer380, C/EBPbeta-PhosphoThr266, and glial fibrillary protein for HSC [10] (Figure 9 A and B).
###end p 69
###begin title 70
###xml 102 107 <span type="species:ncbi:9606">human</span>
Increased expression of active RSK and C/EBPbeta-PhosphoThr217 in activated hepatic stellate cells of human liver fibrosis.
###end title 70
###begin p 71
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
Representative confocal microscopy of 4 patients with severe liver fibrosis and 3 control subjects. A. Activated HSC, identified by confocal microscopy for their morphology and fluorescence for glial fibrillary acidic protein (GFAP; red), displayed activated RSK-PhosphoSer380 in livers of patients with severe liver fibrosis (lower panel) but not in the livers of control subjects (upper panel). Colocalization of RSK-PhosphoSer380 and GFAP is shown in yellow (merge). Nuclei are identified with TO-PRO-3 (blue). Only background staining was observed when omitting the first antibody. B. C/EBPbeta-PhosphoThr217 (green) was present in activated HSC only in livers of patients with liver fibrosis (lower panel). Colocalization of C/EBPbeta-PhosphoThr217 and GFAP (red) is shown in yellow (merge). Nuclei are identified with TO-PRO-3 (blue).
###end p 71
###begin p 72
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 272 277 <span type="species:ncbi:9606">human</span>
Thus, our findings in liver biopsies from patients with liver fibrosis are congruent with the hypothesis we developed in cell-free, cellular and animal models that RSK activation and its phosphorylation of C/EBPbeta in activated HSC may be important in the development of human liver fibrosis.
###end p 72
###begin title 73
Discussion
###end title 73
###begin p 74
###xml 111 114 111 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chung1">[3]</xref>
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier1">[4]</xref>
###xml 117 120 117 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bataller1">[8]</xref>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Iredale1">[33]</xref>
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Friedman3">[34]</xref>
Activation of HSC is responsible for the development of liver fibrosis in chronic liver diseases of all causes [3][4][8], and remarkably, HSC clearance by apoptosis may allow recovery from liver injury and reversal of liver fibrosis [33][34].
###end p 74
###begin p 75
###xml 181 182 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 231 235 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 235 239 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Rudolph1">[16]</xref>
###xml 269 273 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 686 689 677 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chung1">[3]</xref>
###xml 784 786 775 777 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sub>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 249 254 <span type="species:ncbi:10090">mouse</span>
###xml 259 264 <span type="species:ncbi:9606">human</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
In this study we show that activation of RSK and phosphorylation of C/EBPbeta on Thr217 in activated HSC is critical for the progression of liver fibrosis. We used the classical CCl4-induced liver injury and fibrosis model in mice [10][16], primary mouse and human HSC [10], and cell-free systems to investigate the role of RSK and phosphorylation of C/EBPbeta on Thr217 in the activation of HSC and liver fibrosis. It would be important to determine whether RSK and phosphorylation of C/EBPbeta are also critical in other animal models that reflect other causes of human liver fibrosis, such as biliary cirrhosis, alcoholic liver disease, immune liver injury and genetic iron overload [3]. Any one of these studies will require as extensive an analysis as that performed with the CCl4 model of liver fibrosis.
###end p 75
###begin p 76
###xml 151 152 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 181 182 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 257 260 248 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 511 512 493 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 617 620 593 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
We found that mice expressing the RSK-inhibitory C/EBPbeta-Ala217 transgene were refractory to the induction of HSC activation and proliferation by CCl4 treatment. After chronic CCl4 administration, C/EBPbeta was phosphorylated on Thr217 in HSC of C/EBPbeta+/+ mice, but not of C/EBPbeta-Ala217 mice. C/EBPbeta-Ala217 binding to, and blocking, RSK phosphorylation results in decreased phosphorylation of C/EBPbeta on Thr217, and presumably, other target survival proteins by activated RSK. Moreover, chronic CCl4 treatment induced the apoptotic cascade in HSC in the livers of C/EBPbeta-Ala217 mice, but not C/EBPbeta+/+ mice, as determined by the presence of active caspase 8 and 3.
###end p 76
###begin p 77
###xml 494 498 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Micheau1">[29]</xref>
###xml 158 173 <span type="species:ncbi:10090">transgenic mice</span>
###xml 245 250 <span type="species:ncbi:9606">human</span>
C/EBPbeta-Ala217 was present within the death receptor complex II, with active caspase 8, and was linked to apoptosis of activated HSC, freshly isolated from transgenic mice. After blocking the RSK-C/EBPbeta phosphorylation cascade in activated human HSC in culture, with either an ERK1/2 inhibitor or a cell permeant RSK-inhibitory peptide, Ac-KAla217VD-CHO, unphosphorylated C/EBPbeta became associated with other members of the death receptor complex II, such as TNFR1, TRAF2, TRADD and RIP [29]. The combined results suggest a functional link between inactive RSK and the active caspase 8 complex II. Further, inactive RSK and active caspase 8 are co-immunoprecipitated with C/EBPbeta-Ala217 or unphosphorylated C/EBPbeta, suggesting also a physical link. However, identification of a putative RSK/caspase 8 complex would require crystallographic analysis.
###end p 77
###begin p 78
###xml 241 244 235 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 301 305 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Menard1">[35]</xref>
###xml 321 324 312 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 396 400 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Tanaka1">[36]</xref>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 661 676 <span type="species:ncbi:10090">transgenic mice</span>
In support of our proposed role of unphosphorylated and phosphorylated C/EBPbeta-Thr217 on the modulation of HSC survival following their activation by liver injury, expression of the dominant positive phosphorylation mimic C/EBPbeta-Glu217 [5] enhances survival of cultured progenitor neuronal cells [35] while C/EBPbeta-/- macrophages display defective bacterial killing and tumor cytotoxicity [36]. A corollary of our study is that mice expressing the C/EBPbeta-Glu217 transgene would be more susceptible to HSC activation and liver fibrosis induced by liver injury and inflammation. Indeed, this seems to be the case in preliminary studies with these novel transgenic mice (M.B, unpublished observations).
###end p 78
###begin p 79
###xml 131 135 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 373 377 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Yoon1">[37]</xref>
###xml 432 436 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Ranjan1">[38]</xref>
###xml 446 450 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Micheau1">[29]</xref>
###xml 616 620 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
Although the association between C/EBPbeta-PhosphoThr217 and inactive procaspase 8 is linked to the inhibition of active caspase 8 [10], the precise molecular mechanisms by which phosphorylated C/EBPbeta prevents liver injury-induced HSC apoptosis have not been characterized yet. Phosphorylated C/EBPbeta could induce the inhibition of pro-apoptotic proteins, such as p53 [37] or the activation of survival proteins, such as MnSOD [38], or FLIP [29]. Alternatively, granzyme B rather than caspase 8 could be the major target of phosphorylated C/EBPbeta-Thr217, as we suggested previously for HSC apoptosis/survival [10].
###end p 79
###begin p 80
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 63 66 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 563 566 545 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 739 742 718 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 903 907 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 908 912 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-SassoneCorsi1">[14]</xref>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 547 552 <span type="species:ncbi:10090">mouse</span>
###xml 557 562 <span type="species:ncbi:9606">human</span>
###xml 647 651 <span type="species:ncbi:10090">mice</span>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
The hepatotoxin CCl4 induced severe liver fibrosis in C/EBPbeta+/+ mice but not in mice expressing C/EBPbeta-Ala217, a non-phosphorylatable RSK-inhibitory transgene as detected by morphological, semi quantitative and quantitative assays. Blocking phosphorylation of C/EBPbeta-Thr217 through the inhibition of RSK activity with the C/EBPbeta-Ala217 transgene or by C/EBPbeta gene knock-out decreases the fibrotic response of the liver to chronic injury. These findings indicate that the RSK phosphoacceptor site in C/EBPbeta, which is identical in mouse and human [5], is essential for HSC survival upon their activation in chronic liver injury in mice. Further, the decreased fibrotic response of the liver to the hepatotoxin in C/EBPbeta -/- mice suggests that the critical target of RSK in activated HSC is C/EBPbeta-Thr217 rather than other RSK phosphoacceptors in c-Fos, CREB, CBP or other proteins [10]-[14].
###end p 80
###begin p 81
###xml 67 71 67 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Friedman3">[34]</xref>
###xml 228 229 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 594 597 585 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 896 900 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier2">[20]</xref>
###xml 900 904 888 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Matsuoka1">[22]</xref>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
Because liver inflammation induces liver injury and liver fibrosis [34] we assessed the degree of liver injury and the inflammatory response to the hepatotoxin. We found decreased liver injury and inflammation in response to CCl4 treatment in mice expressing the C/EBPbeta-Ala217 transgene. Our data suggest that in addition to increased HSC apoptosis, partial resistance to liver injury and inflammation may contribute to the prevention of liver fibrosis in C/EBPbeta-Ala217 mice. A decreased inflammatory response, mediated at least in part by monocytes/macrophages in the livers of C/EBPbeta+/+ mice, may be responsible for the decreased liver injury in C/EBPbeta-Ala217 mice, since RSK inhibition also affected the recruitment of CD-68+ inflammatory cells to the liver. Our results are congruent with the proposed role of macrophages as a major contributor to liver injury and liver fibrosis [20][22].
###end p 81
###begin p 82
###xml 278 279 272 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 520 523 508 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 114 129 <span type="species:ncbi:10090">transgenic mice</span>
###xml 429 444 <span type="species:ncbi:10090">transgenic mice</span>
Similarly to our findings of RSK inhibition in cell-free, cultured primary stellate cells and in C/EBPbeta-Ala217 transgenic mice, the cell permeant Ac-KAla217VD-CHO peptide prevented the phosphorylation of C/EBPbeta on Thr217 in HSC activated by the liver injury induced by CCl4. Further, and in agreement to our findings of the increased caspase 8 activation in cell-free, cultured primary stellate cells and in C/EBPbeta-A217 transgenic mice, the Ac-KAla217VD-CHO peptide stimulated the apoptotic pathway of C/EBPbeta+/+ HSC as indicated by the presence of active caspase 8 and 3.
###end p 82
###begin p 83
###xml 9 12 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 69 70 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 105 106 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 390 391 387 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 815 818 809 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chung1">[3]</xref>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 694 699 <span type="species:ncbi:9606">human</span>
C/EBPbeta+/+ mice with severe liver fibrosis induced by an 8-week CCl4 treatment, while continuing on CCl4, were treated with the cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK activation, stimulated apoptosis of HSC and blocked active fibrogenesis, preventing progression and inducing regression of liver fibrosis compared to control mice treated with CCl4. Because the resulting activation of HSC and liver fibrosis is similar in any type of chronic liver injury, these results suggest that the inhibition of both RSK and its phosphorylation of C/EBPbeta may be effective in preventing/regressing liver fibrosis in animal models that reflect other causes of human liver fibrosis, such as biliary cirrhosis, alcoholic liver disease, immune liver injury, and genetic iron overload [3].
###end p 83
###begin p 84
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 217 222 <span type="species:ncbi:10090">mouse</span>
###xml 327 338 <span type="species:ncbi:11103">hepatitis C</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 473 478 <span type="species:ncbi:9606">human</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 630 638 <span type="species:ncbi:9606">patients</span>
###xml 850 855 <span type="species:ncbi:9606">human</span>
To assess the relevance of the cellular and animal models of liver fibrosis to human liver fibrosis, we analyzed, in preliminary studies, the role of activated RSK and phosphorylated C/EBPbeta on Thr266 (identical to mouse Thr217 phosphoacceptor) as possible mechanisms leading to increased liver fibrosis. Liver biopsies from hepatitis C patients afflicted with severe liver fibrosis displayed a high level expression of both active, phosphorylated RSK and phosphorylated human C/EBPbeta on Thr266 in activated HSC within the fibrous tissue, compared with samples from control patients. Thus, our findings in liver biopsies from patients with liver fibrosis are congruent with the hypothesis we developed in cell-free, cellular and animal models implicating RSK activation and its phosphorylation of C/EBPbeta in activated HSC in the development of human liver fibrosis.
###end p 84
###begin title 85
Clinical Implications
###end title 85
###begin p 86
###xml 95 100 <span type="species:ncbi:9606">human</span>
Our data indicate that the RSK-C/EBPbeta phosphorylation pathway in HSC is activated in severe human liver fibrosis, and that it is critical for the progression of liver injury to severe liver fibrosis and cirrhosis in an animal model.
###end p 86
###begin p 87
This study suggest that blocking RSK activity inhibits fibrogenesis directly by inducing HSC apoptosis, and indirectly, by reducing liver injury and inflammation. There is no available treatment for liver fibrosis. We speculate that these findings may facilitate the development of small molecules potentially useful in the prevention and treatment of liver fibrosis.
###end p 87
###begin p 88
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Friedman3">[34]</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-3">[39]</xref>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
Both regression of liver fibrosis as well as lack of progression of liver fibrosis, in spite of continued liver injury, as we clearly documented in our study, are considered important clinical targets for patients with chronic liver disease and liver fibrosis [34]. Finally, blocking the progression of liver fibrosis would decrease development of primary liver cancer in these patients since the majority of hepatocellular carcinomas arise in cirrhotic livers [39].
###end p 88
###begin title 89
Material and Methods
###end title 89
###begin title 90
###xml 33 37 <span type="species:ncbi:10090">mice</span>
Construction of C/EBPbeta-Ala217 mice
###end title 90
###begin p 91
###xml 265 269 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 1687 1690 1665 1668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rsv</italic>
###xml 90 105 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 354 359 <span type="species:ncbi:10090">mouse</span>
###xml 679 682 <span type="species:ncbi:9685">cat</span>
###xml 714 717 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 1607 1612 <span type="species:ncbi:10090">Mouse</span>
###xml 1723 1738 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1762 1766 <span type="species:ncbi:10090">mice</span>
###xml 1806 1809 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 1836 1839 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 1876 1879 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 1983 1987 <span type="species:ncbi:10090">mice</span>
###xml 2008 2012 <span type="species:ncbi:10090">mice</span>
###xml 2026 2030 <span type="species:ncbi:10090">mice</span>
###xml 2106 2110 <span type="species:ncbi:10090">mice</span>
The Animal Protocol was approved by the VA Healthcare Center's Veterinarian Medical Unit. Transgenic mice expressing C/EBPbeta-Ala217, a dominant negative, nonphosphorylatable mutation of the C/EBPbeta-Thr217 phosphoacceptor, were generated as described previously [10] and back-crossed to the parental wild-type inbreed FVB mice for >4 generations. The mouse C/EBPbeta cDNA was amplified by PCR to mutate Thr217. The primers used to mutate Thr217 to Ala217 were S 5'-GCC AAG GCC AAG AAG GCG GTG GAC AAG CTG AGC -3'and AS 5'-GCT CAG CTT GTC CAC CGC CTT CTT GGC CTT GGC -3'. C/EBPbeta was removed from pEVRF0 with Apa I and Nhe I and cloned into pHM6 vector (Boehringer-Mannheim, cat. # 1814664) in order to add an RSV promoter upstream to the C/EBPbeta start site. C/EBPbeta was removed from this new construct with Bsa I and Bsp. The 982 bp insert was cloned into mammalian vector pOP13CAT (Stratagene) from which the CAT portion had been previously removed. DNA for pronuclear injection was purified over a CsCl gradient and digested with Ssp I and EclHK I. The 3.6 Kb fragment was separated on gel electrophoresis on a 0.8% gel with no Ethidium Bromide. The appropriate band was removed and electro eluted from the gel using the Elutrap apparatus from Schleicher & Schuell. The eluted DNA was purified with a Qiagen-20 column, precipitated with isopropanol and dissolved in 7.5 mM TRIS pH 7.4, 0.15 mM EDTA. All solutions were prepared with tissue grade water, endotoxin tested (Gibco). Finally the DNA was dialyzed and injected into fertilized ova at a concentration of 1.8 microg/ml, at the Transgenic Mouse Core Facilities, University of California, San Diego. The presence of the rsv gene was used to identify these transgenic mice by PCR, and 3 positive mice resulted. The primer sequences for the RSV PCR were custom designed (RSV.2271 TAGGGTGTGTTTAGGCGAAA sense and RSV.2510 TCTGTTGCCTTCCTAATAAG antisense). The PCR reagents were all from Qiagen. Transgene-bearing founder mice were mated with FVB mice. All founder mice produced viable offspring. This line was bred by mating transgene-positive mice with wild-type FVB and backcrossed to FVB for at least four generations.
###end p 91
###begin title 92
Animal Procedures
###end title 92
###begin p 93
###xml 53 56 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 87 90 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 96 100 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 100 104 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Screpanti1">[40]</xref>
###xml 162 163 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 272 275 256 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 335 336 319 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 510 514 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 688 689 660 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 767 768 739 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
In the chronic exposure to the hepatotoxin, C/EBPbeta+/+, C/EBPbetaAla217 and C/EBPbeta-/- mice [10][40] (23-27 g) each received intraperitoneal injections of CCl4 or mineral oil (50 microl) only once or weekly (for up to 16 weeks). In other chronic experiments, C/EBPbeta+/+ mice (25 g) each received intraperitoneal injections of CCl4 or mineral oil (50 microl) weekly (for up to 16 weeks), but after 8 weeks, animals received either saline (control) or the cell permeant Ac-KAla217VD-CHO (American Peptide) [10] (5 microg IP, three times/week, for week 9, followed by 1 microg IP, three times/week for weeks 10-12 or 10-16) while continuing to induce liver injury and fibrosis with CCl4. In the chronic experiments, animals were sacrificed 24 hr after the last CCl4 injection
###end p 93
###begin p 94
###xml 94 98 94 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 176 180 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck3">[41]</xref>
In the acute exposure to the hepatotoxin, animals received the cell permeant Ac-KAla217VD-CHO [10] (100 microg intraperitoneally) at 18 hr and animals were sacrificed at 24 hr [41].
###end p 94
###begin title 95
Cell cultures
###end title 95
###begin p 96
###xml 15 18 12 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 123 126 117 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 126 130 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 165 172 159 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 309 312 303 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Lee1">[6]</xref>
###xml 40 55 <span type="species:ncbi:10090">transgenic mice</span>
Adult C/EBPbeta+/+ and C/EBPbeta-Ala217 transgenic mice were used for the isolation of hepatic stellate cells as described [5][10]. Stellate cells were prepared, by in situ perfusion and single-step density Nycodenz gradient (Accurate Chemical & Scientific Corp., Westbury, New York), as described previously [6]. Stellate cells were identified by their typical autofluorescence at 328nm excitation wavelength, staining of lipid droplets by oil red, and immunohistochemistry with a monoclonal antibody against desmin. Greater than 95% of the isolated cells were stellate cells.
###end p 96
###begin p 97
###xml 60 63 57 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 109 112 106 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Lee1">[6]</xref>
###xml 264 268 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Primary mouse stellate cells freshly isolated from C/EBPbeta+/+ mice and activated by collagen type 1 matrix [6], were transfected with vectors expressing RSK wild type, a catalytically inactive, dominant negative RSK mutant, or C/EBPbeta-Ala217 together with GFP [10]. Transfected stellate cells were selected by sorting for GFP, and cell lysates were immunoprecipitated with C/EBPbeta specific antibodies. In other experiments, stellate cells were incubated for 24 hr with an ERK1/2 inhibitor (Calbiochem 328006) (10 microM), or the KAVD peptide (200 microM).
###end p 97
###begin title 98
Microscopy
###end title 98
###begin p 99
###xml 235 239 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 271 274 261 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck1">[5]</xref>
###xml 274 278 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
###xml 278 282 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck4">[42]</xref>
###xml 393 397 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck3">[41]</xref>
###xml 599 603 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bedossa1">[18]</xref>
###xml 603 607 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Jimenez1">[19]</xref>
Fluorescent labels were observed using antibodies against C/EBPbeta, RSKPhosphoSer380, alpha-SMA, PCNA (Santa Cruz Biotechnology, Santa Cruz, California), active caspase 3 (PharMingen, San Diego, California) or C/EBPbeta-PhosphoThr217 [10] in a laser confocal microscope [5][10][42]. Fluorochromes utilized were Alexa 488 and Alexa 594. At least 100 cells were analyzed per experimental point [41]. We used TO-PRO-3 (Molecular Probes, Eugene, Oregon) to analyze nuclear morphology. The degree of liver fibrosis was determined by using the Mallory's trichrome and the Sirius red Immunohistochemistry [18][19]. The interobserver agreement was >90%.
###end p 99
###begin title 100
Liver Fibrosis
###end title 100
###begin p 101
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bedossa1">[18]</xref>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Jimenez1">[19]</xref>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Edwards1">[43]</xref>
###xml 557 560 550 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Chojkier1">[4]</xref>
###xml 560 563 553 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Friedman1">[7]</xref>
###xml 563 566 556 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Bataller1">[8]</xref>
We determined the degree of liver fibrosis in coded samples. We evaluated liver fibrosis employing the following methods: i) microscopic morphology; ii) semi-quantitative METAVIR grading system [18] ; iii) collagen type 1 immunofluorescence ; iv) quantitative Sirius red collagen-binding assay as described [19] ; v) quantitative hydroxyproline collagen content as described [43] RT-PCR for collagen type 1; vii) RT-PCR for alpha-smooth muscle actin (present in activated HSC); and viii) RT-PCR for transforming growth factor-beta (a pro-fibrotic cytokine) [4][7][8].
###end p 101
###begin p 102
For measuring hydroxyproline, the liver was excised and a portion was removed and weighed. Hydrolysis of 10 mg tissue/1ml of 6 M HCl was performed at 120degreesC in a pressure vessel for 4 hr. Samples were dried overnight in a vacuum desiccator, diluted to fall into the assay sensitivity range and internal standards were prepared. The chloramine-T reagent was prepared and 1 ml was added to each sample. The samples were incubated for 20 minutes. One ml of aldehyde-perchloric acid reagent was added to each sample and incubated at 60degreesC for 15 minutes. Samples were cooled and absorbance was read at 550nm for samples and standards. Concentrations were determined from the standard curve.
###end p 102
###begin title 103
RT-PCR Analysis
###end title 103
###begin p 104
We isolated total RNA from control and experimental liver samples using Trizol (Invitrogen). Samples were treated with DNase using Turbo DNA-free (Ambion) and precipitated with chloroform as per manufacturer's protocol. cDNA synthesis was performed using 250 ng of total RNA with the AffinityScript Reverse Transcriptase (Stratagene). Specific sets of primers were utilized for each RT-PCR amplification for collagen alpha1 type 1, alpha-SMA and TGF-beta, as described by the manufacturer (SuperArray, Frederick, MD).
###end p 104
###begin title 105
Liver Inflammation Genes
###end title 105
###begin p 106
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
The liver expression of 86 inflammation genes was determined by using the RT2 Quantitative Real-Time PCR Array as described by the manufacturer (SuperArray, Frederick, MD). Control and experimental liver samples were analyzed together with internal control samples for the RNA purification and amplification steps, as well as for housekeeping genes (beta glucuronidase, hypoxanthine guanine phosphoribosyl transferase 1, heat shock protein1beta, glyceraldehyde-3-phosphate dehydrogenase, and beta-actin), using the BioRad iQ5 real-time PCR detection system (BioRad, Hercules, CA). Isolation of total RNA, treatment with DNase, precipitation with chloroform, and cDNA synthesis was performed using 1 microg of total RNA as described for RT-PCR following the manufacturer's recommendations.
###end p 106
###begin title 107
Cyp-2E1 Expression and Activity
###end title 107
###begin p 108
Cyp-2E1 mRNA was measured by RT-PCR in control and experimental liver samples as described above for RT-PCR. Cyp-2E1 protein in liver samples was detected by western blot, following the chemoluminescence protocol (Perkin-Elmer, Shelton, Connecticut) using purified antibodies against Cyp-2E1 (Santa Cruz Biotechnology) as described below.
###end p 108
###begin p 109
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Marks1">[44]</xref>
Cyp-2E1 activity was assessed in a cell-free system, using a recombinant Cyp-2E1 and a specific substrate [44]. Inhibition of Cyp-2E1 activity was achieved using diethyldithiocarbamate (Sigma-Aldrich). We evaluated the effects of the RSK-inhibitory Ac-KAla217VD-CHO peptide (American Peptide) on Cyp-2E1 activity as described per manufacturer (Invitrogen). The standard curve was prepared using dilutions of the fluorescent standard. Master-mix containing the P450 baculosomes reagent, regeneration system, and reaction buffer were added to the designated well of the reaction plate. The plate was incubated for 20 minutes at room temperature to allow the compounds to interact with the Cyp-2E1 in the absence of enzyme turnover. The reaction plate was pre-read at this point to measure any auto-fluorescence. The reaction was initiated with the addition of the reaction mixture containing substrate and NADP. The plate was incubated for 30 minutes, and the fluorescence was measured at 400 and 460 nm. Data analysis was performed as suggested by the manufacturer.
###end p 109
###begin title 110
Immunoprecipitation and Immunoblots
###end title 110
###begin p 111
###xml 417 421 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Descombes1">[45]</xref>
###xml 555 559 538 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck3">[41]</xref>
###xml 559 563 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck5">[46]</xref>
###xml 563 567 546 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Trautwein1">[47]</xref>
###xml 830 834 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Buck2">[10]</xref>
Pre-cleared stellate cell lysates were incubated for 2 h with purified C/EBPbeta, RSK, TRADD or caspase 8 antibodies followed by the addition of A/G+ agarose (Santa Cruz Biotechnology) for 12 h. The immunoprecipitation reactions each contained 500 microg of total protein and 2 microg antibody (or purified IgG pre-immune serum as negative control). Immunoprecipitates were washed 3 times in 500 ml cell lysis buffer [45] and resolved by SDS-PAGE, and C/EBPbeta, RSK, RSKp380, TNFR-1, TRADD, RIP, TRAF-2, beta-actin and caspase 8 detected by western blot [41][46][47], following the chemoluminescence protocol (Perkin-Elmer, Shelton, Connecticut) using purified antibodies against C/EBPbeta (C-19; aa 258-276), RSK, RSKp380, TRADD, RIP, beta-actin (Santa Cruz Biotechnology), procaspase 8 (PharMingen) and C/EBPbeta-PhosphoThr217 [10]. Negative samples were performed omitting the first antibody.
###end p 111
###begin title 112
Caspase Activity
###end title 112
###begin p 113
###xml 580 584 580 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Stennicke1">[48]</xref>
###xml 759 760 759 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 922 926 922 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Thornberry1">[49]</xref>
###xml 926 930 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001372-Stennicke2">[50]</xref>
###xml 175 180 <span type="species:ncbi:9606">human</span>
Purified synthetic N-acetyl, C-aldehyde KAVD tetrapeptide (American Peptide Company, Sunnyvale, California) were assayed for their ability to enhance the activity of purified human recombinant caspase 8 (catalogue # 201-041-C005) (Alexis Biochemicals). The sequence of caspase 8 includes S217 through D479 cloned into an expression vector containing a 21 amino acid linker at the N-terminus. Thus, the prodomain (first 220 amino acids) is essentially missing. The fragment is cleaved at D385 and the active caspase 8 is essentially identical to that identified in apoptotic cells [48]. Caspase 8 activity was also measured in stellate cell lysates, using recombinant caspase 8 as a standard for activity. Caspase activity was determined by the release of the p-nitroanaline colorimetric (Alexis Biochemicals, San Diego, California) substrate for caspase 8 (catalogue # 260-045) within the linear part of the kinetic assay [49][50]. Active caspase 3 was determined with specific antibodies (PharMingen).
###end p 113
###begin title 114
RSK Activity
###end title 114
###begin p 115
RSK activity was measured by the QTL Lightspeed assay (QTL Biosystems; Santa Fe, New Mexico) using purified recombinant RSK-2 (4,333 U/mg) (Upstate, New York), and staurosporine (0.01 nM) as a control inhibitor. RSK activity was measured in the presence or absence of Ac-KThr217VD-CHO (200 microM), Ac-KAla217VD-CHO (200 microM), or C/EBPbeta216-253-Ala217 (0.25 nM) peptides.
###end p 115
###begin title 116
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Livers
###end title 116
###begin p 117
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 80 91 <span type="species:ncbi:11103">hepatitis C</span>
###xml 320 325 <span type="species:ncbi:9606">Human</span>
We obtained anonymous, de-identified liver samples from 4 patients with chronic hepatitis C viral infection and severe liver fibrosis (Metavir scores of 3 or 4) (53+/-17 years) and from 3 control subjects without liver disease (60+/-13 years) (NDRI). The protocol was approved by the University of California, San Diego Human Protection Program.
###end p 117
###begin title 118
Statistical Analysis
###end title 118
###begin p 119
###xml 58 59 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 229 230 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Results are expressed as mean (+/-SD). Either the Student-t or the Wilcoxon Mann-Whitney tests were used to evaluate the differences of the means between groups for parametric and non-parametric populations, respectively, with a P value of <0.05 as significant.
###end p 119
###begin title 120
Supporting Information
###end title 120
###begin p 121
###xml 54 55 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 114 115 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 172 173 169 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
C/EBPbeta-Ala217 mice have less liver damage after CCl4 treatment. Animals received either mineral oil [MO] or CCl4. Thirty hours after a single intraperitoneal dose of CCl4 C/EBPbeta+/+ (n: 9) and C/EBPbeta-/- (n: 9) mice had higher serum alanine aminotransferase (ALT) levels than C/EBPbeta- Ala217 mice (n: 9) (P<0.005 ). Results are representative of three independent experiments.
###end p 121
###begin p 122
(0.02 MB DOC)
###end p 122
###begin p 123
Click here for additional data file.
###end p 123
###begin p 124
###xml 122 123 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 179 200 173 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and methods</xref>
###xml 287 288 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 448 449 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 96 100 <span type="species:ncbi:10090">Mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 348 350 <span type="species:ncbi:10090">NS</span>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
###xml 511 513 <span type="species:ncbi:10090">NS</span>
###xml 784 786 <span type="species:ncbi:10090">NS</span>
Transgenic C/EBPbeta-Ala217 and C/EBPbeta+/+ mice have similar Cyp-2E1 expression in the liver. Mice were treated with CCl4 or control mineral oil for 24 or 72 hr as described in Materials and methods. A. Liver Cyp-2E1 RNA as determined by RT-PCR was comparable at baseline and after CCl4 treatment in C/EBPbeta +/+ [wt] and C/EBPbeta-Ala217 mice (NS). B. Liver Cyp-2E1 protein as determined by western blot was comparable at baseline and after CCl4, treatment in C/EBPbeta +/+ [wt] and C/EBPbeta- Ala217 mice (NS). C. Cyp-2E1 activity as determined in a cell free system using a recombinant Cyp-2E1 protein was comparable in the absence or presence of the RSK-inhibitory Ac-KAVD-CHO peptide (1-1000 ng/ml). Values are expressed as percentage of control Cyp-2E1 activity (open bars) (NS). A specific Cyp-2E1 inhibitor was used as a positive control (closed bar).
###end p 124
###begin p 125
(0.66 MB TIF)
###end p 125
###begin p 126
Click here for additional data file.
###end p 126
###begin p 127
###xml 410 417 401 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g007">Fig. 7B</xref>
###xml 629 636 614 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g007">Fig. 7C</xref>
The association of C/EBPbeta with active caspase 8, TNFR1, TRAF2, TRADD and RIP is induced by inhibiting RSK in HSC. A Reciprocal TRADD immunoprecipitation of experiment described in (7A) confirmed the association of unphosphorylated C/EBPbeta with active caspase 8. beta - Actin was used as an internal control for the immunoprecipitations. B. Reciprocal TNFR1 immunoprecipitation of experiment described in (Fig. 7B) confirmed the association of unphosphorylated C/EBPbeta with TNFR1. beta- Actin was used as an internal control for the immunoprecipitations. C. Reciprocal TRAF2 immunoprecipitation of experiment described in (Fig. 7C) confirmed the association of unphosphorylated C/EBPbeta with TRAF2. beta- Actin was used as an internal control for the immunoprecipitations.
###end p 127
###begin p 128
(0.56 MB TIF)
###end p 128
###begin p 129
Click here for additional data file.
###end p 129
###begin p 130
###xml 200 221 197 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and methods</xref>
###xml 348 369 345 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and methods</xref>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
###xml 122 127 <span type="species:ncbi:10090">mouse</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 457 459 <span type="species:ncbi:10090">NS</span>
Primary mouse hepatocytes are refractory to the induction of apoptosis by the RSK-inhibitory Ac-KAVD-CHO peptide. Primary mouse hepatocytes were isolated from C/EBP beta +/+ [wt] mice as described in Materials and methods. Cells were treated with Ac-KAVD-CHO peptide for 18 hr. Apoptosis was measured by the annexin-V binding assay as described in Materials and methods. The peptide did not induce hepatocyte apoptosis when compared to control hepatocytes (NS).
###end p 130
###begin p 131
(0.18 MB TIF)
###end p 131
###begin p 132
Click here for additional data file.
###end p 132
###begin p 133
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 110 122 110 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001372-g008">Fig 8E and F</xref>
###xml 309 310 306 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 66 70 <span type="species:ncbi:10090">Mice</span>
The RSK-inhibitory peptide blocks liver fibrosis induced by CCl4. Mice were from the experiment described in (Fig 8E and F). Representative Sirius red immunohistochemistry for collagen (in red; arrowhead). Marked increase in liver collagen in a cirrhotic pattern was observed in C/EBPbeta +/+ treated with CCl4 but not in animals receiving the RSK-inbitory peptide.
###end p 133
###begin p 134
(0.18 MB TIF)
###end p 134
###begin p 135
Click here for additional data file.
###end p 135
###begin p 136
We thank J Blenis for the RSK expression vectors, Daniela Traykova, Melissa Mitrou, Antimone Dewing, and Janel Suburu for technical assistance and Marcus Kouma for the preparation of the figures.
###end p 136
###begin title 137
References
###end title 137
###begin article-title 138
Reducing Risks, Promoting Healthy Life.
###end article-title 138
###begin article-title 139
Report 04-5491. Executive Summary.
###end article-title 139
###begin article-title 140
Cirrhosis and its Complications.
###end article-title 140
###begin article-title 141
Regulation of collagen gene expression.
###end article-title 141
###begin article-title 142
###xml 19 22 <span type="species:ncbi:10116">rat</span>
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBPb is required for hepatocyte proliferation induced by TGFa.
###end article-title 142
###begin article-title 143
Activation of hepatic stellate cells by TGFa and collagen type I is mediated by oxidative stress through c-myb expression.
###end article-title 143
###begin article-title 144
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.
###end article-title 144
###begin article-title 145
Liver Fibrosis.
###end article-title 145
###begin article-title 146
Hepatic stellate cells.
###end article-title 146
###begin article-title 147
C/EBPb phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival.
###end article-title 147
###begin article-title 148
Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.
###end article-title 148
###begin article-title 149
The protein kinase p90 Rsk as an essential mediator of cytostatic factor activity.
###end article-title 149
###begin article-title 150
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rsk</sup>
###xml 42 49 <span type="species:ncbi:8355">Xenopus</span>
Induction of metaphase arrest in cleaving Xenopus embryos by the protein kinase p90Rsk.
###end article-title 150
###begin article-title 151
Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3.
###end article-title 151
###begin article-title 152
The signal-dependent coactivator CBP is a nuclear target for pp90RSK.
###end article-title 152
###begin article-title 153
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery.
###end article-title 153
###begin article-title 154
Modeling liver fibrosis in rodents.
###end article-title 154
###begin article-title 155
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 99 110 <span type="species:ncbi:11103">hepatitis C</span>
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.
###end article-title 155
###begin article-title 156
Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method.
###end article-title 156
###begin article-title 157
###xml 113 117 <span type="species:ncbi:10090">mice</span>
D-Galactosamine hepatotoxicity is associated with endotoxin-sensitivity and mediated by lymphoreticular cells in mice.
###end article-title 157
###begin article-title 158
###xml 23 26 <span type="species:ncbi:10116">rat</span>
Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium.
###end article-title 158
###begin article-title 159
Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor b: implication for a pathogenetic role in alcoholic liver fibrogenesis.
###end article-title 159
###begin article-title 160
Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR.
###end article-title 160
###begin article-title 161
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.
###end article-title 161
###begin article-title 162
Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids.
###end article-title 162
###begin article-title 163
Troglitazone and liver injury: in search of answers.
###end article-title 163
###begin article-title 164
Oxidative and reductive metabolism by cytochrome P450 2E1.
###end article-title 164
###begin article-title 165
Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.
###end article-title 165
###begin article-title 166
Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes.
###end article-title 166
###begin article-title 167
###xml 50 72 <span type="species:ncbi:75985">Mannheimia haemolytica</span>
###xml 89 95 <span type="species:ncbi:9913">Bovine</span>
Inflammatory Cytokines Enhance the Interaction of Mannheimia haemolytica Leukotoxin with Bovine Peripheral Blood Neutrophils In Vitro.
###end article-title 167
###begin article-title 168
N-Ac-DEVD-N'-(Polyfluorobenozoyl)-R110: novel cell-permeable fluorogenic caspase substrates for the detection of caspase activity and apoptosis.
###end article-title 168
###begin article-title 169
Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis.
###end article-title 169
###begin article-title 170
Stellate cell behavior during resolution of liver injury.
###end article-title 170
###begin article-title 171
Reversal of hepatic fibrosis-fact or fantasy?
###end article-title 171
###begin article-title 172
An essential role for a MEK-C/EBP pathway during growth factor-regulated cortical neurogenesis.
###end article-title 172
###begin article-title 173
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages.
###end article-title 173
###begin article-title 174
Decreased survival of C/EBP[beta]-deficient keratinocytes is due to aberrant regulation of p53 levels and function.
###end article-title 174
###begin article-title 175
C/EBb regulates TNF induced MnSOD expression and protection against apoptosis.
###end article-title 175
###begin article-title 176
Report 04-5491. Liver Cancer.
###end article-title 176
###begin article-title 177
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Lymphoproliferative disorder and imbalanced T-helper response in C/EBPb-deficient mice.
###end article-title 177
###begin article-title 178
LAP (NF-IL6), a tissue-specific transcriptional activator, is an inhibitor of hepatoma cell proliferation.
###end article-title 178
###begin article-title 179
Nuclear export of phosphorylated C/EBPb mediates the inhibition of albumin expression by TNFa.
###end article-title 179
###begin article-title 180
Modified assay for determination of hydroxyproline in a tissue hydrolyzate.
###end article-title 180
###begin article-title 181
A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.
###end article-title 181
###begin article-title 182
LAP, a novel member of the C/EBP gene family, encodes a liver-enriched transcriptional activator protein.
###end article-title 182
###begin article-title 183
###xml 70 76 <span type="species:ncbi:10090">murine</span>
Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants.
###end article-title 183
###begin article-title 184
Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain.
###end article-title 184
###begin article-title 185
Biochemical characteristics of caspases -3, -6, -7, and -8.
###end article-title 185
###begin article-title 186
A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.
###end article-title 186
###begin article-title 187
Caspase assays.
###end article-title 187
###begin p 188
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 188
###begin p 189
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Grants from the NIDDK, NCI, and the Department of Veterans Affairs
###end p 189

